Erick Saldanha, Medical Oncologist and Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, shared a post on X:
“Thrilled to share our paper, just out in the Annals of Oncology, ESMO.
We assessed the role of ctDNA clearance as a biomarker of neoadjuvant immune checkpoint blockade response for patients with solid tumours. Proud to be part of this effort alongside a brilliant group of colleagues and my dear friend Valenza Carmine.
Luís Felipe Leite, Medical Student at Universidade Federal Fluminense, shared Erick Saldanha‘s post on X, adding:
“Absence of ctDNA clearance may identify patients unlikely to achieve pCR after neoadjuvant ICIs.
However, limited specificity means current evidence does not support its use to guide treatment de-escalation. Impressive analysis by Dr. Saldanha in the Annals of Oncology.”
Authors: Valenza Carmine, Erick Saldanha et al.
Learn more about immunotherapy on OncoDaily.